ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Infinity Pharmaceuticals, Inc." (INFI) Report Updated: Dec 15, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Infinity Pharmaceuticals, Inc." (INFI)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: ANAC, CBST, FOLD, ACHN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: B down upgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Infinity Pharmaceuticals, Inc."© quotemedia

Company Profile

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. The company’s lead product candidates include IPI-145, an inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase; Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase, which completed Phase 1 clinical trial. It is also pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. The IPI-145 is in an ongoing, Phase 1 dose-escalation trial in patients with advanced hematologic malignancies and in a Phase 2a signal-finding study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase 2a signal-finding study in patients with rheumatoid arthritis. The Retaspimycin HCl is in a Phase 2 trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC); and in a Phase 1b/2 trial in combination with everolimus in approximately 45 NSCLC patients with a KRAS mutation. The company is headquartered in Cambridge, Massachusetts.

Recent News: "Infinity Pharmaceuticals, Inc."